Astralis Ltd., partnered with SkyPharma PLC, has initiated a phase I clinical trial in the United States for Psoraxine, a new injectable treatment for moderate psoriasis.
The Weekly Roundup: July 22-26
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Emerging Therapeutic for Non-Segmental Vitiligo: Merck’s MK-6194
The Cutaneous Connection: Enhancing Vitiligo Care With Nanette Silverberg, MD
Study Highlights Efficacy of Lotion with Biotechnological Phytocomplex, Niacinamide, and Succinic Acid in Enhancing Microbiota Diversity and Reducing Acne Severity
The FDA Approves Deuruxolitinib for Severe Alopecia in Adults